Is a complete AMLX research report available?

No complete published report is available for Amylyx Pharmaceuticals, Inc. (AMLX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Amylyx Pharmaceuticals, Inc. (AMLX)

NASDAQ: AMLX · USD

$19.7

+0.18 (+0.9%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-30 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AMLX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	2.2B
Net income (ttm)	-150.1M
EPS (ttm)	-$1.49
Shares out	111.2M
Volume	2,070,717
Beta	-0.20
Price target	$24.9	+26.2%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -150.1M
EPS (ttm): -$1.49
Market cap: 2.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AMLX indicators

Market & fundamental data

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001658551
Company name	Amylyx Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	03237H101
Employees	136
Employees Change	13%
Employees Change Percent	10.57
Enterprise value	$1.9B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Industry PE	90.42
Industry PE Fwd	14.46
IPO Date	2022-01-07
Isin	US03237H1014
Last refreshed	2026-07-30
Market cap	$2.2B
Market cap category	Mid-Cap
Price	$19.73
Price currency	USD
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2834
Symbol	AMLX
Website	https://amylyx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-6.84%
FCF yield	-5.49%
P/B ratio	8.02x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-95.9M
Net Income	$-150.1M
Net Income Growth Years	1%
Profit Per Employee	$-1.1M
ROA	-38.79
Roa5y	-42.6
ROCE	-28.41
ROE	-63.26
Roe5y	-86.06
ROIC	-41.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	147.09%
Cagr3y	-4.34%
EPS Growth Quarters	5
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$293.6M
Cash	$279.8M
Current Assets	$285M
Current Liabilities	$16M
Debt	$5.6M
Debt Equity	$0.02
Equity	$273.2M
Liabilities	$20.4M
Long Term Assets	$8.6M
Long Term Liabilities	$4.5M
Net Cash	$274.1M
Net Cash By Market Cap	$12.5
Net Cash Growth	35.25%
Net Debt Equity	$-1
Tangible Book Value	$273.2M
Tangible Book Value Per Share	$2.46
WACC	3.16

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	17.85
Net Working Capital	$-9.6M
Quick ratio	17.53
Working Capital	$269.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-38.81%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	146.93%
200-day SMA	14.77
3Y total return	-12.47%
50-day SMA	16.11
50-day SMA vs 200-day SMA	50over200
All Time High	41.93
All Time High Change	-52.95%
All Time High Date	2023-01-30
All Time Low	1.58
All Time Low Change	1,152.7%
All Time Low Date	2024-06-17
ATR	1.12
Beta	-0.2
Beta1y	0.95
Beta2y	1.46
Ch YTD	63.33
High	20.21
High52	20.21
High52 Date	2026-07-29
High52ch	-2.38%
Low	19.05
Low52	7.48
Low52 Date	2025-08-08
Low52ch	163.77%
Ma50ch	22.49%
Price vs 200-day SMA	33.57%
RSI	65.37
RSI Monthly	63.25
RSI Weekly	66.9
Sharpe ratio	1.72x
Sortino ratio	3
Total Return	-38.81%
Tr YTD	63.33
Tr1m	10.91%
Tr1w	11.47%
Tr3m	20.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	8
Analyst Price Target Top	$26.71
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.35
Operating Income	$-159.3M
Price target	$24.89
Price Target Change	$26.15
Price Target Change Top	$35.38

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	82,381,328%
Float Percent	74.09%
Net Borrowing	190,736,000
Shares Insiders	7.76%
Shares Institutions	87.15%
Shares Out	111,186,317
Shares Qo Q	0.66%
Shares Yo Y	38.81%
Short Float	14.89%
Short Ratio	6.93
Short Shares	11.03

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-147.5M
Adjusted OCF	-147,333,000
Average Volume	1,577,058.8x
Bv Per Share	2.46
CAPEX	$-127,000
Ch1m	10.91
Ch1w	11.47
Ch1y	146.9
Ch3m	20.97
Ch3y	-12.47
Ch6m	36.02
Change	0.92%
Change From Open	1.18
Close	19.55
Days Gap	-0.26
Depreciation Amortization	467,000
Dollar Volume	40,855,246.4
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-78.9M
EBITDA	$-78.4M
EPS	$-1.49
F Score	2
FCF	$-120.5M
FCF EV Yield	-6.28x
FCF Per Share	$-1.08
Financing CF	194,584,000
Fiscal Year End	December
Founded	2,014
Income Tax	$46,000
Investing CF	93,960,000
Ipr	3.84
Iprfo	-6.05
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-03
Ma150	15.11
Ma150ch	30.62%
Ma20	18.15
Ma20ch	8.71%
Net CF	168,909,000
Next Earnings Date	2026-08-10
Open	19.5
Optionable	Yes
Position In Range	58.62
Post Close	19.73
Postmarket Change Percent	-1.63
Postmarket Price	$19.41
Ppne	5,093,000
Price Date	2026-07-29
Ptbv Ratio	8.03
Relative Volume	1.31x
Share Based Comp	26,932,000
Tr6m	36.02%
Us State	Massachusetts
Volume	2,070,717

Amylyx Pharmaceuticals, Inc. (AMLX)

Coverage state: Market snapshot only — no published research

Generate the first AMLX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AMLX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AMLX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AMLX

Frequently asked questions